- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | HCW Biologics Inc.: HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results | 29 | GlobeNewswire (Europe) | MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| Fr | HCW Biologics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Fr | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | HCW Biologics Inc.: HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 22.10. | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
| 16.10. | HCW Biologics Inc.: HCW Biologics to Participate in the 2025 Maxim Growth Summit | 1 | GlobeNewswire (USA) | ||
| 16.10. | HCW Biologics Inc.: HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer | 1 | GlobeNewswire (USA) | ||
| 16.10. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program | 1 | GlobeNewswire (USA) | ||
| 18.09. | HCW Biologics Inc.: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing | 1 | GlobeNewswire (USA) | ||
| 16.09. | HCW Biologics Inc.: HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development | 270 | GlobeNewswire (Europe) | Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in... ► Artikel lesen | |
| 12.09. | Why Is HCW Biologics Stock Surging 102% Overnight? | 3 | Benzinga.com | ||
| 09.09. | HCW Biologics Inc.: HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program | 261 | GlobeNewswire (Europe) | HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious... ► Artikel lesen | |
| 05.09. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform | 1 | Benzinga.com | ||
| 25.08. | HCW Biologics meldet vielversprechende Ergebnisse für neue Krebs-Immuntherapie | 15 | Investing.com Deutsch | ||
| 25.08. | HCW Biologics stock soars on novel cancer immunotherapy breakthrough | 1 | Investing.com | ||
| 25.08. | HCW Biologics reports promising results for new cancer immunotherapy | 1 | Investing.com | ||
| 25.08. | HCW Biologics Inc.: HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market | 3 | GlobeNewswire (USA) | ||
| 19.08. | HCW Biologics erhält Delisting-Mitteilung von der NASDAQ und plant Anhörung | 3 | Investing.com Deutsch |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 33,540 | -0,80 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 40,850 | -7,77 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| QIAGEN | 38,165 | -1,37 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen anlässlich der jüngst präsentierten Quartalszahlen von 50 auf 46 Euro gesenkt, die Einstufung aber auf "Buy" belassen.... ► Artikel lesen | |
| EVOTEC | 5,290 | -2,97 % | Evotec-Aktie: Das Grauen nimmt kein Ende - Wer soll das noch kaufen? | © Foto: fn SymbolbildBei Evotec herrscht das blanke Chaos. Die Zahlen sind miserabel, die Aktie stürzt ins Bodenlose, und ein Ende ist nicht in Sicht. Der Hamburger Wirkstoffentwickler kämpft mit massiven... ► Artikel lesen | |
| BIONTECH | 88,65 | -0,06 % | BioNTech: Analysten sehen Aktie nach Zahlen im neuen Licht | Die jüngsten Quartalszahlen von BioNTech führten in dieser Woche zu unterschiedlichen Einschätzungen zweier Analystenhäuser. Während UBS das Kursziel leicht anhebt, bleibt Jefferies deutlich positiver.... ► Artikel lesen | |
| NUVALENT | 96,50 | +2,05 % | Nuvalent kündigt Präsentation zulassungsrelevanter Daten für Lungenkrebs-Wirkstoff an | ||
| AVIDITY BIOSCIENCES | 70,80 | -0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| INVIVYD | 2,345 | +32,49 % | Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights | PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarterOctober 2025 ending cash and cash equivalents... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,135 | -4,50 % | Change at the top of Recursion as co-founder leaves CEO role | ||
| ARCUTIS BIOTHERAPEUTICS | 25,070 | +9,67 % | Arcutis completes enrollment in infant atopic dermatitis study | ||
| KYMERA THERAPEUTICS | 64,94 | +2,21 % | Kymera Therapeutics: Stifel bekräftigt "Buy"-Rating im Vorfeld entscheidender Daten | ||
| PRAXIS PRECISION MEDICINES | 186,07 | +4,49 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 22,770 | +11,56 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| VERA THERAPEUTICS | 28,350 | -0,07 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 36,810 | +5,17 % | Structure Therapeutics stock holds Outperform rating at BMO ahead of key data |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,560 (+22,95 %) liegt der Kurs bei 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.